150 related articles for article (PubMed ID: 9889704)
1. [The first original Russian class-III antiarrhythmic nibentan].
Glushkov RG; Golitsyn SP; Dorodnikova EV; Maĭkov EB; Mashkovskiĭ MD; Merkulova IN; Rozenshtraukh LV; Ruda MIa; Skachilova SIa; Chazov EI; Iuzhakov SD
Vestn Ross Akad Med Nauk; 1998; (11):38-41. PubMed ID: 9889704
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation.
Fedorov VV; Sharifov OF; Beloshapko GG; Yushmanova AV; Rosenshtraukh LV
J Cardiovasc Pharmacol; 2000 Jul; 36(1):77-89. PubMed ID: 10892664
[TBL] [Abstract][Full Text] [Related]
3. [Comparative study of electrophysiological mechanisms of anti-arrhythmia III class agents, cardiocyclide, nibentan, and sotalol during experimental myocardial infarction and sympathetic stimulation].
Kaverina NV; Lyskovtsev VV; Popova EP
Eksp Klin Farmakol; 2003; 66(1):27-33. PubMed ID: 12683077
[TBL] [Abstract][Full Text] [Related]
4. [Effect of the class III antiarrhythmic drug nibentan in vagotonic atrial fibrillation].
Popova EP; Lyskovtsev VV; Kaverina NV
Eksp Klin Farmakol; 2006; 69(1):24-7. PubMed ID: 16579055
[TBL] [Abstract][Full Text] [Related]
5. [The cholinolytic activity of the new anti-arrhythmia preparation Nibentan].
Fedorov VV; Vinogradova TM; Bogdanov KIu; Rozenshtraukh LV
Ross Fiziol Zh Im I M Sechenova; 1999 Mar; 85(3):383-94. PubMed ID: 10494589
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study of the electrophysiological properties of class iii medicinals (cardiocyclide, nibentan, sotalol) and evaluation of their efficacy in atrial fibrillation produced by auricular and vagal stimulation].
Kaverina NV; Lyskovtsev VV; Popova EP
Eksp Klin Farmakol; 2007; 70(1):11-6. PubMed ID: 17402585
[TBL] [Abstract][Full Text] [Related]
7. [Novel antiarrhythmic class III drug nibentan: from experimental studies to clinical practice].
Rosenshtraukh LV; Ruda MIa; Golitsyn SP; Maĭkov EB
Kardiologiia; 2003; 43(6):66-8. PubMed ID: 12974257
[No Abstract] [Full Text] [Related]
8. Dofetilide, a novel class III antiarrhythmic agent.
Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
[TBL] [Abstract][Full Text] [Related]
9. [Development of original Russian antiarrhythmic drugs of the 3rd class].
Rozenshtraukh LV; Chazov EI; Glushkov RG; Golitsyn SP; Ruda MIa; Iuzhakov SD; L'vov AI
Vestn Ross Akad Med Nauk; 2003; (12):61-5. PubMed ID: 14724976
[No Abstract] [Full Text] [Related]
10. Effect of class III antiarrhythmic preparation nibentan on extrasystolic and post-extrasystolic contraction of rat papillary muscle.
Afanas'ev SA; Lukavskaya IA; Ugdyzhekova DS; Popov SV; Antonchenko IV; Abubakirova GO; Medvedev MA
Bull Exp Biol Med; 2002 Jul; 134(1):15-7. PubMed ID: 12459857
[TBL] [Abstract][Full Text] [Related]
11. [New pharmacodynamic effects of gidazepam and befol in patients with cardiac arrhythmias].
Skibitskiĭ VV; Kanorskiĭ SG
Eksp Klin Farmakol; 1993; 56(5):23-7. PubMed ID: 7906171
[TBL] [Abstract][Full Text] [Related]
12. Dofetilide: a new class III antiarrhythmic agent.
Roukoz H; Saliba W
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
[TBL] [Abstract][Full Text] [Related]
13. Myocardial contractility after in vitro treatment with class III antiarrhythmic drug Nibentan.
Latfullin IA; Gaifullina RF; Dzhordzhikiya RK; Nigmatullina RR
Bull Exp Biol Med; 2006 Jan; 141(1):81-3. PubMed ID: 16929971
[TBL] [Abstract][Full Text] [Related]
14. Model systems for the discovery and development of antiarrhythmic drugs.
Nattel S; Duker G; Carlsson L
Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
Shenasa M; Assadi H; Heidary S; Shenasa H
Card Electrophysiol Clin; 2016 Jun; 8(2):467-79. PubMed ID: 27261835
[TBL] [Abstract][Full Text] [Related]
16. [A new class-III antiarrhythmic preparation among the dicyclohexylamides of aminocarboxylic acids].
Kaverina NV; Lyskovtsev VV; Sokolov SF; Poppe H; Marx D; Kishchuk EP; Turilova AI; Likhosherstov AM; Tsorin IB; Chichkanov GG
Vestn Ross Akad Med Nauk; 1998; (11):42-6. PubMed ID: 9889705
[TBL] [Abstract][Full Text] [Related]
17. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential.
Nair LA; Grant AO
Cardiovasc Drugs Ther; 1997 Apr; 11(2):149-67. PubMed ID: 9140692
[TBL] [Abstract][Full Text] [Related]
18. [Electrophysiological effects and mechanisms of antiarrhythmic action of nibentan in patients with paroxysmal arrhythmias].
Golitsin SP
Kardiologiia; 2003; 43(4):64-73. PubMed ID: 12968607
[No Abstract] [Full Text] [Related]
19. Dofetilide: a new pure class III antiarrhythmic agent.
Falk RH; Decara JM
Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
[TBL] [Abstract][Full Text] [Related]
20. [The effect of novel class III anti-arrhythmia agents cardiocyclide and nibentan during activation of cardiac beta-adrenoreceptors].
Turilova AI; Katsitadze NSh; Kaverina NV
Eksp Klin Farmakol; 2002; 65(5):29-30. PubMed ID: 12596510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
